An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates
INT18404
Phase 1 other active
Quick answer
An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates for Dermatitis atopic is a Phase 1 program (other) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Dermatitis atopic
- Phase
- Phase 1
- Modality
- other
- Status
- active